Top Page
Allergy Therapeutics
(LSE:AGY)
Allergy Therapeutics (AGY) vs. S&P 500 (SPY)
Allergy Therapeutics Business Overview & Revenue Model
Allergy Therapeutics Financial Statement Overview
| Breakdown | ||||
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 55.20M | 59.59M | 72.77M | 84.33M | 78.20M | Gross Profit |
| 29.74M | 32.69M | 48.95M | 61.80M | 57.51M | EBIT |
| -35.26M | -34.85M | -13.00M | 2.64M | 4.46M | EBITDA |
| -30.74M | -36.24M | -8.69M | 7.61M | 11.69M | Net Income Common Stockholders |
| -40.22M | -43.07M | -13.78M | 2.89M | 7.06M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 12.91M | 14.85M | 20.52M | 40.27M | 36.96M | Total Assets |
| 64.83M | 66.77M | 72.95M | 88.09M | 86.22M | Total Debt |
| 30.99M | 35.99M | 10.53M | 11.17M | 12.18M | Net Debt |
| 18.07M | 21.14M | -9.99M | -29.10M | -24.78M | Total Liabilities |
| 61.12M | 64.70M | 35.18M | 39.55M | 42.44M | Stockholders Equity |
| 3.71M | 2.07M | 37.77M | 48.53M | 43.78M |
| Cash Flow | Free Cash Flow | |||
| -35.54M | -35.59M | -17.17M | 5.95M | 9.73M | Operating Cash Flow |
| -32.14M | -30.92M | -14.11M | 8.52M | 12.28M | Investing Cash Flow |
| -1.20M | -4.67M | -3.06M | -2.76M | -2.77M | Financing Cash Flow |
| 31.43M | 29.91M | -2.64M | -2.03M | -110.00K |
Allergy Therapeutics Technical Analysis
Allergy Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | £157.23B | 28.55 | 17.43% | 2.42% | 14.82% | 14.98% | |
75 Outperform | £7.62B | 18.00 | 10.83% | 2.05% | -3.32% | 20.38% | |
71 Outperform | £55.18B | 21.56 | 19.06% | 4.56% | 3.46% | -48.06% | |
68 Neutral | £4.17B | 14.82 | 15.79% | 3.28% | 5.83% | 83.35% | |
51 Neutral | $5.20B | 3.18 | -40.80% | 2.96% | 17.66% | 1.94% | |
48 Neutral | £300.29M | ― | -369.20% | ― | 4.50% | 74.32% |
Allergy Therapeutics Corporate Events
Allergy Therapeutics reported a financial turnaround with a £1.9 million operating profit before R&D and other costs, and a 4% revenue growth on a constant currency basis for the six months ended December 2024. The company has strengthened its financial position with a cash reserve of £21.7 million and has made significant progress in its clinical programs, including the submission of a Marketing Authorisation Application for Grass MATA MPL in Germany and promising interim results from its VLP Peanut allergy vaccine trial. These developments position the company to advance its strategic priorities and potentially transform patient care in allergy treatment.
Allergy Therapeutics has advanced to the final phase of its VLP Peanut Phase I/IIa PROTECT trial, with healthy volunteers receiving the highest doses without any safety signals. The trial aims to establish a strong safety margin and determine the optimal dose range for future studies. The company also announced a new publication validating the vaccine’s mechanism of action, highlighting its potential to reduce allergic responses and promote protective immune mechanisms. The results are promising for addressing the unmet need for effective peanut allergy treatments and could lead to long-term protection.
Allergy Therapeutics has announced new long-term incentive awards for its senior executive team and share option awards for all employees. These awards aim to incentivize share price growth and operational performance over five years, with specific performance targets set. The initiative reflects the company’s strategy to enhance its market position and shareholder value.
Allergy Therapeutics announced its participation in the 2025 AAAAI/WAO Joint Congress, where it will present scientific advancements in its pollen and food-allergy research portfolio. The company will showcase six posters, including a positive comparative assessment of its Grass MATA MPL immunotherapy, design details of a Phase III trial for grass allergies in children, and safety data from a clinical trial of a peanut allergy vaccine. These developments highlight Allergy Therapeutics’ commitment to innovation and its efforts to transform patient lives through advanced therapies.
Allergy Therapeutics has announced the publication of successful results from their G306 Phase III trial for Grass MATA MPL in the journal Allergy. The trial demonstrated a 20.3% reduction in symptoms compared to placebo, surpassing the efficacy of other similar treatments in the past decade. This new treatment, requiring only six injections, offers a significant improvement in quality of life for patients and positions Allergy Therapeutics as a leader in innovative allergy solutions.
Allergy Therapeutics has granted share option awards to key members of its management team, aligning their interests with those of the company’s stakeholders to drive future growth. These options, which are contingent on meeting performance criteria over three years, aim to incentivize management and encourage long-term value creation for shareholders.
Allergy Therapeutics has reported a financial turnaround with a 4% growth in half-year revenues and improvements in its cash position, indicating recovery and stability. The company has made significant strides in its allergy treatment programs, submitting a Marketing Authorisation Application for its Grass MATA MPL product and beginning a Phase III trial for pediatric patients. Encouraging interim data from its VLP Peanut PROTECT Trial shows potential efficacy in reducing skin sensitivity, supporting the transformative potential of its peanut allergy vaccine candidate.